"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","treatment_protocol_ch1","growth_protocol_ch1","molecule_ch1","extract_protocol_ch1","extract_protocol_ch1.1","taxid_ch1","description","data_processing","data_processing.1","data_processing.2","data_processing.3","data_processing.4","platform_id","contact_name","contact_email","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","data_row_count","instrument_model","library_selection","library_source","library_strategy","relation","relation.1","supplementary_file_1","agent:ch1","cell line:ch1","rna source:ch1"
"GSM1754830","Untreated MCF7 cells","GSM1754830","Public on Jul 01 2015","Jul 01 2015","May 15 2019","SRA","1","MCF7 breast cancer cells","Homo sapiens","cell line: MCF7","agent: control","rna source: cells","Human breast cancer MCF7 cells were grown in cell culture medium supplemented with exosome-depleted serum for 3 days and treated with 100 μM DHA for 24 h. Whole exosomes were collected from the conditioned medium of DHA-treated and untreated MCF7 cells.","The cells were cultivated in DMEM medium supplemented with exosome-depleted 10 % fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Cells were routinely maintained in a humidified chamber at 37 °C and 5 % CO2.","total RNA","Total RNA was extracted from the cells and exosomes using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), according to the manufacturer’s protocol.","A small RNA library was prepared from 100 ng of total RNA using the TruSeq Small RNA Preparation Kit (Illumina, San Diego, CA).","9606","Control Cell","The reads were mapped onto the human genome (build 36, Mar 2006) and intersected with microRNAs (mirBase.org) using GeneSifter Software (PerkinElmer, Santa Clara CA).","Reads were normalized to the mapped reads and significant differences in reads were determined using the Likelihood Ratio Test and the Benjamini and Hochberg post-test.","Genome_build: hg18, mirBase release 13","Supplementary_files_format_and_content: miRBase_normalized_reads.txt","Supplementary_files_format_and_content: Supplemental_File_1_Likelihood_Ratio_Test.xlsx","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03835446","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1078751","NONE","control","MCF7","cells"
"GSM1754831","DHA-treated MCF7 cells","GSM1754831","Public on Jul 01 2015","Jul 01 2015","May 15 2019","SRA","1","MCF7 breast cancer cells","Homo sapiens","cell line: MCF7","agent: DHA","rna source: cells","Human breast cancer MCF7 cells were grown in cell culture medium supplemented with exosome-depleted serum for 3 days and treated with 100 μM DHA for 24 h. Whole exosomes were collected from the conditioned medium of DHA-treated and untreated MCF7 cells.","The cells were cultivated in DMEM medium supplemented with exosome-depleted 10 % fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Cells were routinely maintained in a humidified chamber at 37 °C and 5 % CO2.","total RNA","Total RNA was extracted from the cells and exosomes using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), according to the manufacturer’s protocol.","A small RNA library was prepared from 100 ng of total RNA using the TruSeq Small RNA Preparation Kit (Illumina, San Diego, CA).","9606","DHA Cell","The reads were mapped onto the human genome (build 36, Mar 2006) and intersected with microRNAs (mirBase.org) using GeneSifter Software (PerkinElmer, Santa Clara CA).","Reads were normalized to the mapped reads and significant differences in reads were determined using the Likelihood Ratio Test and the Benjamini and Hochberg post-test.","Genome_build: hg18, mirBase release 13","Supplementary_files_format_and_content: miRBase_normalized_reads.txt","Supplementary_files_format_and_content: Supplemental_File_1_Likelihood_Ratio_Test.xlsx","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03835447","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1078752","NONE","DHA","MCF7","cells"
"GSM1754832","Untreated MCF7 exosomes","GSM1754832","Public on Jul 01 2015","Jul 01 2015","May 15 2019","SRA","1","MCF7 breast cancer exosomes","Homo sapiens","cell line: MCF7","agent: control","rna source: exosomes","Human breast cancer MCF7 cells were grown in cell culture medium supplemented with exosome-depleted serum for 3 days and treated with 100 μM DHA for 24 h. Whole exosomes were collected from the conditioned medium of DHA-treated and untreated MCF7 cells.","The cells were cultivated in DMEM medium supplemented with exosome-depleted 10 % fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Cells were routinely maintained in a humidified chamber at 37 °C and 5 % CO2.","total RNA","Total RNA was extracted from the cells and exosomes using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), according to the manufacturer’s protocol.","A small RNA library was prepared from 100 ng of total RNA using the TruSeq Small RNA Preparation Kit (Illumina, San Diego, CA).","9606","Control Exosome","The reads were mapped onto the human genome (build 36, Mar 2006) and intersected with microRNAs (mirBase.org) using GeneSifter Software (PerkinElmer, Santa Clara CA).","Reads were normalized to the mapped reads and significant differences in reads were determined using the Likelihood Ratio Test and the Benjamini and Hochberg post-test.","Genome_build: hg18, mirBase release 13","Supplementary_files_format_and_content: miRBase_normalized_reads.txt","Supplementary_files_format_and_content: Supplemental_File_1_Likelihood_Ratio_Test.xlsx","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03835448","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1078753","NONE","control","MCF7","exosomes"
"GSM1754833","DHA-treated MCF7 exosomes","GSM1754833","Public on Jul 01 2015","Jul 01 2015","May 15 2019","SRA","1","MCF7 breast cancer exosomes","Homo sapiens","cell line: MCF7","agent: DHA","rna source: exosomes","Human breast cancer MCF7 cells were grown in cell culture medium supplemented with exosome-depleted serum for 3 days and treated with 100 μM DHA for 24 h. Whole exosomes were collected from the conditioned medium of DHA-treated and untreated MCF7 cells.","The cells were cultivated in DMEM medium supplemented with exosome-depleted 10 % fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Cells were routinely maintained in a humidified chamber at 37 °C and 5 % CO2.","total RNA","Total RNA was extracted from the cells and exosomes using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), according to the manufacturer’s protocol.","A small RNA library was prepared from 100 ng of total RNA using the TruSeq Small RNA Preparation Kit (Illumina, San Diego, CA).","9606","DHA Exosome","The reads were mapped onto the human genome (build 36, Mar 2006) and intersected with microRNAs (mirBase.org) using GeneSifter Software (PerkinElmer, Santa Clara CA).","Reads were normalized to the mapped reads and significant differences in reads were determined using the Likelihood Ratio Test and the Benjamini and Hochberg post-test.","Genome_build: hg18, mirBase release 13","Supplementary_files_format_and_content: miRBase_normalized_reads.txt","Supplementary_files_format_and_content: Supplemental_File_1_Likelihood_Ratio_Test.xlsx","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03835449","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1078754","NONE","DHA","MCF7","exosomes"
